Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
influenza vaccine Fluarix, Adjuvanted Fluarix · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| influenza vaccine Fluarix, Adjuvanted Fluarix | BIOLOGICAL | - |
Inclusion Criteria: * A male or female aged over 65 years at the time of the revaccination; who previously received the adjuvanted candidate vaccine or Fluarix during a clinical study organized during the preceeding year Exclusion Criteria: * Use of any investigational or non-registered product (...
Top 6 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 1 | PHASE3 | mRNA-1018-H5 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Flu/COVID-19 mRNA combination vaccine |
Adjuvanted Fluarix is an investigational influenza vaccine developed by GSK plc. It is an adjuvanted candidate vaccine designed to prevent influenza disease, and it has been studied specifically in an elderly population aged 65 years and older. It remains in clinical development rather than being an approved product.
It is being studied to prevent influenza disease, with the clinical program focused on the elderly population aged 65 years and older. The only recorded trial enrolled healthy volunteers in this age group. It is an investigational candidate and is not described as an approved product for any use.
GSK plc, which trades under the ticker GSK, is the developer of the adjuvanted Fluarix influenza vaccine candidate. GSK sponsored the clinical work evaluating this adjuvanted formulation in older adults.
The adjuvanted Fluarix vaccine is in Phase 1 development. One Phase 1 trial has been recorded for this candidate, and that trial is completed, with no active trials currently listed. It is an investigational vaccine and is not described as FDA approved.
One trial is recorded: NCT00318058, titled Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population. It was a completed Phase 1 study in Belgium with 84 enrolled participants aged 65 years and older, and it was an uncontrolled study.
Adjuvanted Fluarix refers to an adjuvanted formulation of the Fluarix influenza vaccine, developed by GSK plc. The adjuvanted version is an investigational candidate studied in a Phase 1 trial in older adults, while the program described here covers that adjuvanted formulation specifically.